What findings were reported in ACCORD trial regarding glycemic control in individuals with HF?
In the ACCORD trial, which examined whether a therapeutic strategy targeting normal HbA1c (ie, <6.0%) would reduce the rate of cardiovascular events compared with a strategy targeting HbA1c levels from 7.0% to 7.9% in diabetic patients with established cardiovascular disease (CVD) or high CVD risk, 5% of individuals (n=494) had HF at baseline. There was an unexpected finding of increased mortality in the intensive treatment arm compared with the standard therapy arm, and this increased hazard was not statistically different in patients with and without HF at baseline (interaction P=0.71).